Japan · Delayed Price · Currency is JPY MedRx Statistics
Total Valuation
MedRx has a market cap or net worth of JPY 4.11 billion. The enterprise value is 2.97 billion.
| Market Cap | 4.11B |
| Enterprise Value | 2.97B |
Important Dates
The next confirmed earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MedRx has 68.53 million shares outstanding. The number of shares has increased by 23.04% in one year.
| Current Share Class | 68.53M |
| Shares Outstanding | 68.53M |
| Shares Change (YoY) | +23.04% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 8.49% |
| Owned by Institutions (%) | 7.45% |
| Float | 61.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.98 |
| PB Ratio | 2.58 |
| P/TBV Ratio | 2.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 24.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.99
| Current Ratio | 13.99 |
| Quick Ratio | 12.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.61% and return on invested capital (ROIC) is -31.62%.
| Return on Equity (ROE) | -49.61% |
| Return on Assets (ROA) | -29.79% |
| Return on Invested Capital (ROIC) | -31.62% |
| Return on Capital Employed (ROCE) | -53.22% |
| Weighted Average Cost of Capital (WACC) | 7.38% |
| Revenue Per Employee | 5.76M |
| Profits Per Employee | -40.90M |
| Employee Count | 21 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.11 |
Taxes
In the past 12 months, MedRx has paid 13.00 million in taxes.
| Income Tax | 13.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.89% in the last 52 weeks. The beta is 0.57, so MedRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -54.89% |
| 50-Day Moving Average | 63.04 |
| 200-Day Moving Average | 83.20 |
| Relative Strength Index (RSI) | 48.16 |
| Average Volume (20 Days) | 699,360 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedRx had revenue of JPY 121.00 million and -859.00 million in losses. Loss per share was -14.58.
| Revenue | 121.00M |
| Gross Profit | 118.00M |
| Operating Income | -876.00M |
| Pretax Income | -846.00M |
| Net Income | -859.00M |
| EBITDA | -868.00M |
| EBIT | -876.00M |
| Loss Per Share | -14.58 |
Balance Sheet
The company has 1.14 billion in cash and no debt, with a net cash position of 1.14 billion or 16.68 per share.
| Cash & Cash Equivalents | 1.14B |
| Total Debt | n/a |
| Net Cash | 1.14B |
| Net Cash Per Share | 16.68 |
| Equity (Book Value) | 1.59B |
| Book Value Per Share | 26.40 |
| Working Capital | 1.25B |
Cash Flow
In the last 12 months, operating cash flow was -895.00 million and capital expenditures -85.00 million, giving a free cash flow of -980.00 million.
| Operating Cash Flow | -895.00M |
| Capital Expenditures | -85.00M |
| Depreciation & Amortization | 8.00M |
| Net Borrowing | n/a |
| Free Cash Flow | -980.00M |
| FCF Per Share | -14.30 |
Margins
| Gross Margin | 97.52% |
| Operating Margin | -723.97% |
| Pretax Margin | -699.17% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MedRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -23.04% |
| Shareholder Yield | -23.04% |
| Earnings Yield | -20.89% |
| FCF Yield | -23.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedRx has an Altman Z-Score of 21.72 and a Piotroski F-Score of 1.
| Altman Z-Score | 21.72 |
| Piotroski F-Score | 1 |